Diem Nguyen tapped to lead 'point of in­flec­tion' at Xalud Ther­a­peu­tics; Di­ana Es­co­lar dances her way to Avro­bio CMO

Diem Nguyen con­sid­ers her­self a “point of in­flec­tion seer.”

Help­ing busi­ness­es strate­gize and scale up is “where my sweet spot is,” the Pfiz­er vet­er­an said. So when she was tapped to take the helm at gene ther­a­py-fo­cused Xalud Ther­a­peu­tics, she knew it would be a great fit.

Xalud, found­ed in 2009 and head­quar­tered in New York City, is work­ing on non-vi­ral gene ther­a­pies to treat patho­log­ic in­flam­ma­tion. The com­pa­ny’s lead can­di­date, XT-150, is a lo­cal­ly in­jectable plas­mid DNA gene ther­a­py ex­press­ing In­ter­leukin 10 (IL-10) — an up­stream mod­u­la­tor for many pro-in­flam­ma­to­ry and an­ti-in­flam­ma­to­ry me­di­a­tors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER